No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PRTA Prothena
- 24.380
- +0.800+3.39%
Close Jul 22 16:00 ET
- 23.900
- -0.480-1.97%
Post 17:23 ET
1.31BMarket Cap-7595P/E (TTM)
24.470High23.165Low380.09KVolume23.790Open23.580Pre Close9.12MTurnover0.99%Turnover RatioLossP/E (Static)53.77MShares70.09052wk High2.61P/B934.75MFloat Cap18.69052wk Low--Dividend TTM38.34MShs Float79.749Historical High--Div YieldTTM5.53%Amplitude5.640Historical Low24.004Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Prothena (NASDAQ:PRTA) Spikes 17% This Week, Taking Five-year Gains to 144%
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really flourishing, you can make more than 100%. Long term Prothena Corporation plc (
Prothena Price Target Maintained With a $28.00/Share by RBC Capital
Prothena Price Target Maintained With a $28.00/Share by RBC Capital
Prothena Corp Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 38.82% RBC Capital $28 → $28 Reiterates Sector Perform → Sector Perform 05/09/2024 311.5% JMP S
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $28
RBC Capital analyst Brian Abrahams maintains $Prothena(PRTA.US)$ with a hold rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 49.2% and a tot
Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
Pinning Down Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Difficult Right Now
It's not a stretch to say that Prothena Corporation plc's (NASDAQ:PRTA) price-to-sales (or "P/S") ratio of 12.3x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in t
Comments
Investors may miss opportunities or face setbacks if there's no rational basis for the P/S ratio. The moderate P/S ratio suggests investors anticipate a slowdown in revenue. Many investors, less bearish than analysts, hold onto their stocks, risking future disappointment if P/S aligns with growth outlook.
What Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Not Telling YouAnalysts are forecasting that Prothena will reach break-even point before it might exhaust its cash runway. Given its impressive revenue growth and reduction in cash burn, Prothena appears well positioned to fund further growth with minimal shareholder dilution or borrowing.
Despite recent declines, the company's strong growth signals a potential investment opportunity. Market response to its revenue growth indicates interest despite lack of profits.
Overvaluation risk looms for Prothena's shares with high P/S ratio amid poor revenue and weak growth forecast. Investors may face disappointment if the share price realigns with the firm's bleak future outlook.
$Prothena(PRTA.US$. Up up up
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg